Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: A novel remedy in LUTS?
Apoptosis
/ drug effects
Cell Line
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Humans
Lower Urinary Tract Symptoms
Male
Methoxamine
/ pharmacology
Muscle Contraction
/ drug effects
Muscle, Smooth
/ drug effects
Norepinephrine
/ pharmacology
Prostate
/ cytology
Stromal Cells
/ cytology
Thalidomide
/ pharmacology
benign prostatic hyperplasia (BPH)
lower urinary tract symptoms (LUTS)
prostate smooth muscle contraction
prostate stromal cell proliferation
thalidomide
α1-adrenoceptors
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
02
07
2020
accepted:
19
02
2021
pubmed:
10
3
2021
medline:
30
12
2021
entrez:
9
3
2021
Statut:
ppublish
Résumé
Medical treatment in benign prostatic hyperplasia targets prostate size to prevent disease progression, complications, and surgery, and prostate smooth muscle tone for rapid relief of lower urinary tract symptoms. Combination therapies are still required to target both at once. However, current medications are insufficient, due to an unfavorable balance between side effects and efficacy. The limited efficacy of α Cytoskeletal organization was visualized by phalloidin staining, cell growth was assessed by 5-ethynyl-2'-deoxyuridine assay, cell viability by cell counting kit-8, and apoptosis and cell death by flow cytometry in cultured prostate stromal cells (WPMY-1). Contractions of human prostate tissues from radical prostatectomy were studied in an organ bath, where they were induced by the α Thalidomide significantly reduced the proliferation of WPMY-1 cells, which was time- and concentration-dependent (10-300 µM). In parallel, organization of actin filaments collapsed after treatment with thalidomide. Thalidomide (30-100 µM) inhibited noradrenaline-, phenylephrine-, and methoxamine-induced contractions, as well as nonadrenergic contractions induced by endothelin-1 and U46619, and neurogenic contractions induced by EFS. No reduction in viability and no increases in apoptosis or in cell death were observed in WPMY-1 cells. Thalidomide impairs the growth of human prostate stromal cells, without showing a decrease in cell viability. In parallel, thalidomide inhibits adrenergic, neurogenic, and nonadrenergic contractions. This may be explained by a breakdown of the actin cytoskeleton. In vivo, urodynamic effects of thalidomide appear possible and may even exceed those of α
Sections du résumé
BACKGROUND
Medical treatment in benign prostatic hyperplasia targets prostate size to prevent disease progression, complications, and surgery, and prostate smooth muscle tone for rapid relief of lower urinary tract symptoms. Combination therapies are still required to target both at once. However, current medications are insufficient, due to an unfavorable balance between side effects and efficacy. The limited efficacy of α
METHODS
Cytoskeletal organization was visualized by phalloidin staining, cell growth was assessed by 5-ethynyl-2'-deoxyuridine assay, cell viability by cell counting kit-8, and apoptosis and cell death by flow cytometry in cultured prostate stromal cells (WPMY-1). Contractions of human prostate tissues from radical prostatectomy were studied in an organ bath, where they were induced by the α
RESULTS
Thalidomide significantly reduced the proliferation of WPMY-1 cells, which was time- and concentration-dependent (10-300 µM). In parallel, organization of actin filaments collapsed after treatment with thalidomide. Thalidomide (30-100 µM) inhibited noradrenaline-, phenylephrine-, and methoxamine-induced contractions, as well as nonadrenergic contractions induced by endothelin-1 and U46619, and neurogenic contractions induced by EFS. No reduction in viability and no increases in apoptosis or in cell death were observed in WPMY-1 cells.
CONCLUSIONS
Thalidomide impairs the growth of human prostate stromal cells, without showing a decrease in cell viability. In parallel, thalidomide inhibits adrenergic, neurogenic, and nonadrenergic contractions. This may be explained by a breakdown of the actin cytoskeleton. In vivo, urodynamic effects of thalidomide appear possible and may even exceed those of α
Substances chimiques
Thalidomide
4Z8R6ORS6L
Methoxamine
HUQ1KC1YLI
Norepinephrine
X4W3ENH1CV
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
377-389Informations de copyright
© 2021 The Authors. The Prostate published by Wiley Periodicals LLC.
Références
Gravas S, Cornu JN, Drake MJ, et al. Management of non-neurogenic male LUTS. EAU Guidelines Edn. Presented at: EAU Annual Congress; March 16-20, 2018; Copenhagen, Denmark.
Hennenberg M, Stief CG, Gratzke C. Prostatic alpha1-adrenoceptors: new concepts of function, regulation, and intracellular signaling. Neurourol Urodyn. 2014;33:1074-1085.
Fusco F, Creta M, de Nunzio C, Gacci M, Li Marzi V, Finazzi Agro E. Alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: a systematic review and meta-analysis of urodynamic studies. Neurourol Urodyn. 2018;37(6):1865-1874.
Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118-140.
Ventura S, Oliver V, White CW, Xie JH, Haynes JM, Exintaris B. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol. 2011;163:891-907.
Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108:1132-1138.
Michel MC, Mehlburger L, Bressel HU, Goepel M. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1998;1:332-335.
Cindolo L, Pirozzi L, Fanizza C, et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2014;68(3):418-425.
Hennenberg M, Acevedo A, Wiemer N, et al. Non-adrenergic, tamsulosin-insensitive smooth muscle contraction is sufficient to replace alpha1-adrenergic tension in the human. Prostate. 2017;77:697-707.
Hennenberg M, Miljak M, Herrmann D, et al. The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle. Am J Physiol Renal Physiol. 2013;305:F1383-F1390.
Strittmatter F, Gratzke C, Weinhold P, et al. Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms. Eur J Pharmacol. 2011;650:650-655.
Joglekar S, Levin M. The promise of thalidomide: evolving indications. Drugs Today (Barc). 40, 2004:197-204.
Fujita K, Asami Y, Murata E, Akita M, Kaneko K. Effects of thalidomide, cytochrome P-450 and TNF-alpha on angiogenesis in a three-dimensional collagen gel-culture. Okajimas Folia Anat Jpn. 2002;79:101-106.
Moehler T. Clinical experience with thalidomide and lenalidomide in multiple myeloma. Curr Cancer Drug Targets. 2012;12:372-390.
Arai H, Furusu A, Nishino T, et al. Thalidomide prevents the progression of peritoneal fibrosis in mice. Acta Histochem Cytochem. 2011;44:51-60.
Lv P, Meng Q, Liu J, Wang C. Thalidomide accelerates the degradation of extracellular matrix in rat hepatic cirrhosis via down-regulation of transforming growth factor-beta1. Yonsei Med J. 2015;56:1572-1581.
Liu X, Qian L, Nan H, Cui M, Hao X, Du Y. Function of the transforming growth factor-beta1/c-Jun N-terminal kinase signaling pathway in the action of thalidomide on a rat model of pulmonary fibrosis. Exp Ther Med. 2014;7:669-674.
Sales AM, de Matos HJ, Nery JA, Duppre NC, Sampaio EP, Sarno EN. Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy. Braz J Med Biol Res. 2007;40:243-248.
Walker SL, Waters MF, Lockwood DN. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev. 2007;78:197-215.
Leonard GD, Dahut WL, Gulley JL, Arlen PM, Figg WD. Docetaxel and thalidomide as a treatment option for androgen-independent, nonmetastatic prostate cancer. Rev Urol. 2003;5(suppl 3):S65-S70.
Fernández-Martínez E, Ponce-Monter H, Soria-Jasso L, et al. Inhibition of uterine contractility by thalidomide analogs via phosphodiesterase-4 inhibition and calcium entry blockade. Molecules. 2016;21:21.
Seto SW, Bexis S, McCormick PA, Docherty JR. Actions of thalidomide in producing vascular relaxations. Eur J Pharmacol. 2010;644:113-119.
Seto SW, Docherty JR. Effects of T-type calcium channel blockers and thalidomide on contractions of rat vas deferens. Br J Pharmacol. 2010;159:1211-1216.
Pradidarcheep W, Wallner C, Dabhoiwala NF, Lamers WH. Anatomy and histology of the lower urinary tract. In: Andersson KE, Michel M, eds. Urinary Tract. Handbook of Experimental Pharmacology. Vol 2011. Berlin, Heidelberg: Springer; 2011: 117-148. https://doi.org/10.1007/978-3-642-16499-6_7
Shaikhibrahim Z, Lindstrot A, Ellinger J, et al. The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key? Mol Med Rep. 2012;5:313-316.
Stark T, Livas L, Kyprianou N. Inflammation in prostate cancer progression and therapeutic targeting. Transl Androl Urol. 2015;4:455-463.
Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009;55:864-873.
Orsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2013;10:49-54.
Kunit T, Gratzke C, Schreiber A, et al. Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate. Am J Physiol Renal Physiol. 2014;307:F823-F832.
Webber MM. A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis. 1999;20:1185-1192.
Puck TT, Marcus PI. Action of x-rays on mammalian cells. J Exp Med. 1956;103:653-666.
Rafehi H, Orlowski C, Georgiadis GT, Ververis K, El-Osta A, Karagiannis TC. Clonogenic assay: adherent cells. J Vis Exp. 2011.
Michel MC, Murphy TJ, Motulsky HJ. New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology. Mol Pharmacol. 2020;97:49-60.
Curtis MJ, Alexander S, Cirino G, et al. Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Br J Pharmacol. 2018;175:987-993.
Curtis MJ, Bond RA, Spina D, et al. Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol. 2015;172:3461-3471.
Liu Y, Huang X, He X, et al. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. FASEB J. 2015;29:4829-4839.
Eter N, Spitznas M. DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture. Br J Ophthalmol. 2002;86:1303-1305.
Ng SS, Gutschow M, Weiss M, et al. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res. 2003;63:3189-3194.
Chueh SC, Guh JH, Chen J, Lai MK, Ko FN, Teng CM. Inhibition by tamsulosin of tension responses of human hyperplastic prostate to electrical field stimulation. Eur J Pharmacol. 1996;305:177-180.
Guh JH, Ko FN, Chueh SC, Lai MK, Teng CM. Ouabain-induced increases in resting tone of human hyperplastic prostate following repeated noradrenaline and electrical field stimulation. Br J Pharmacol. 1996;117:1716-1720.
Davis B, Goepel M, Bein S, Chess-Williams R, Chapple CR, Michel MC. Lack of neuropeptide Y receptor detection in human bladder and prostate. BJU Int. 2000;85:918-924.
Füllhase C, Chapple C, Cornu JN, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013;64:228-243.
Chapple CR, Montorsi F, Tammela TLJ, Wirth M, Koldewijn E, Fernández Fernández E. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59:342-352.
Madan RA, Karzai FH, Ning YM, et al. Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. BJU Int. 2016;118:590-597.
de Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016;13:613-626.
Ho CK, Habib FK. Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol. 2011;8:29-41.
Balint B, Yin H, Chakrabarti S, Chu MW, Sims SM, Pickering JG. Collectivization of vascular smooth muscle cells via TGF-beta-cadherin-11-dependent adhesive switching. Arterioscler Thromb Vasc Biol. 2015;35:1254-1264.
Eichner R, Heider M, Fernández-Sáiz V, et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med. 2016;22:735-743.
Domingo S, Sole C, Moline T, Ferrer B, Ordi-Ros J, Cortes-Hernandez J. Efficacy of thalidomide in discoid lupus erythematosus: insights into the molecular mechanisms. Dermatology. 2020;236:467-476.
Moehler TM, Hillengass J, Glasmacher A, Goldschmidt H. Thalidomide in multiple myeloma. Curr Pharm Biotechnol. 2006;7:431-440.
Wang X, Li S, Meng Z, Liu T, Zhang X. Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis. PLOS One. 2014;9:e107593.